Canaccord initiated coverage of Pulse Biosciences with a Buy rating and $32 price target. The company has a "differentiated" cardiac ablation platform to meet the needs of electrophysiologists, the analyst tells investors in a research note. The firm says electrophysiologists ablation market represents a $3B opportunity that is growing at 10%-15% annually. It believes Pulse's nanosecond pulsed field ablation can gain "significant" market share.
